Olanzapine-induced hyperglycemia: Role of humoral insulin resistance-inducing factors [1]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 2, 2005, Pages 183-185

  Laimer, Markus ^a   Ebenbichler, Christoph F ^a   Kranebitter, Michael ^a   Eder, Ursula ^a   Mangweth, Barbara ^a   Weiss, Elisabeth ^a   Hofer, Alex ^a   Hummer, Martina ^a   Kemmler, Georg ^a   Lechleitner, Monika ^a   Patsch, Josef R ^a   Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; CLOZAPINE; FATTY ACID; OLANZAPINE; RESISTIN; RISPERIDONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; BLOOD SAMPLING; BODY FAT; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; LYMPHOCYTE FUNCTION; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

BENZODIAZEPINES; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; PROSPECTIVE STUDIES;

EID: 20144366971     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000155827.05327.88     Document Type: Letter

References (16)

1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
2. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158:1719-1722.
3. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
4. Melkersson K, Khan A, Hilding A, et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol. 2001;11:327-332.
5. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918-2923.
6. Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry. 2003;64:1436-1439.
7. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
8. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111:716-723.
9. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
10. Hotamisligil GS, Peraldi P, Budavari A, et al. 1RS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-668.
11. Schuld A, Kraus T, Haack M, et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res. 2000;43:164-166.
12. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481.
13. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
14. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
15. Togo T, Kojima K, Shoji M, et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol. 2004;19:37-40.
16. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.